Stryker Corporation
SYK Healthcare Medical - Devices NYSE
$364.56
$-5.94 (-1.60%)
Open: $366.57 | High: $368.25 | Low: $356.28 | Prev Close: $370.50
Market Cap: $139.51B
Volume: 1.2M | Avg: 1.9M
Last updated: March 09, 2026 at 02:04 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 527
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 44.03 |
| P/B Ratio | 6.22 |
| P/S Ratio | 5.55 |
| EPS | $8.28 |
| Beta | 0.87 |
| Shares Outstanding | 382.69M |
| 52-Week High | $404.87 |
| 52-Week Low | $329.16 |
| SMA 50 | $365.09 |
| SMA 200 | $374.43 |
| Dividend Yield | 0.93% |
| Annual Dividend | $3.40 |
| Next Earnings | April 30, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 63.5% |
| Operating Margin | 22.4% |
| Net Margin | 12.9% |
| ROE | 15.0% |
| ROA | 6.8% |
| Debt/Equity | 0.66 |
| Current Ratio | 1.89 |
| Quick Ratio | 1.21 |
Balance Sheet
| Total Assets | $47.84B |
| Total Liabilities | $25.42B |
| Total Equity | $22.42B |
|
|
|
| Cash | $4.01B |
| Total Debt | $14.86B |
| Net Debt | $10.85B |
Income Statement
| Revenue | $25.12B |
| Gross Profit | $16.07B |
| Operating Income | $4.89B |
| Net Income | $3.25B |
|
|
|
| EBITDA | $6.31B |
| Revenue/Share | $65.66 |
Cash Flow
| Operating CF | $5.04B |
| CapEx | $761.00M |
| Free Cash Flow | $4.28B |
|
|
|
| Book Value/Share | $58.61 |
| Tangible Book/Share | $-6.67 |
| Equity/Share | $58.61 |
Technical Indicators
| RSI (14) | 44.54 Neutral |
| MACD |
3.38
Signal: 4.79
|
| Volatility | 27.45% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -7.63% |
| Sharpe Ratio | -0.52 Poor |
| Volatility (Ann.) | 20.24% Moderate |
| SYK (1Y) | -7.63% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -20.67% |
Sector Comparison (Healthcare)
| Metric | SYK | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 44.03 | 27.34 | 83% |
| P/B Ratio | 6.22 | -19.64 | 77% |
| ROE (%) | 15.04% | -9.57% | 60% |
| Net Margin (%) | 12.92% | 9.25% | 51% |
| Stock Score | 527 | 544.0 | 32% |
| 1Y Return (%) | -7.63 % | +8.45 % | 31% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYK | $364.56 | $376.77 | $379.68 | $378.49 | $365.15 | $374.44 | 44.54 | 3.38 | 27.45% | 509630 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the SYK stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| SYK | Intuitive Surgical Reveals Cyber Breach | Neutral | feeds.benzinga.com | Read More |
| SYK | A Cyberattack Just Put Stryker's $25 Billion Growth Story to the Test | Positive | 247wallst.com | Read More |
| SYK | Invesco Rising Dividends Fund Q4 2025 Portfolio Activity | Neutral | seekingalpha.com | Read More |
| SYK | Stock Of The Day: Where Is The Bottom For Stryker? | Neutral | benzinga.com | Read More |
| SYK | Stryker Shares Fall 2.5% as Cyberattack Disrupts Ordering and Shipping Systems | Negative | gurufocus.com | Read More |
Recent Insider Trading
No recent insider trading data available for SYK
Company Information
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
| CEO | Kevin A. Lobo |
| Employees | 53000 |
| Country | US |
| IPO Date | 1980-03-17 |
| Exchange | NYSE |
| Website | https://www.stryker.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category